David E. Avigan, MD

David E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.

David E. Avigan, MD, discusses research surrounding CAR T-cell therapy in lymphoproliferative diseases.